ArticleJournal of medical case reports2026
Effects of hypothalamic phospholipid treatment in three patients with neurological disorders: a case series.
Article in Journal of medical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHypothalamic phospholipids, essential components of neuronal membranes, play a key role in neuroendocrine regulation and synaptic plasticity. Liposom Forte, an injectable formulation based on hypothalamic phospholipids, has been proposed as an adjuvant in neurological disorders characterized by cerebral metabolic-functional impairment. The aim was to evaluate the effect of Liposom Forte on cognitive functions and neurological symptoms in three patients with different conditions: drug-resistant epilepsy with comorbid depression, mild cognitive impairment, and chronic cerebrovascular disease. Patients received intramuscular Liposom Forte (28 mg/day) in 15-day cycles per month for a total duration of 3 months. Pre- and post-treatment Mini Mental State Examination score, subjective symptoms, and any adverse events were collected. CASES PRESENTATION: The series included three white patients: a 28-year-old man, a 70-year-old woman, and a 76-year-old man. Two out of three patients exhibited clinical improvement, documented either by an increase in Mini Mental State Examination scores or by self-reported symptomatic benefits. One patient reported an unexpected improvement in lower limb paresthesia. No clinical changes were observed in the patient with post-ischemic stroke sequelae; however, the Mini Mental State Examination was maintained within the normal ranges. The treatment was well tolerated in all cases, with no adverse events reported.
conclusionLiposom Forte demonstrated a favorable tolerability profile and preliminary signals of efficacy in cognitive and affective domains in patients with heterogeneous neurological conditions. Despite variability in clinical response, two patients showed signs of benefit, and the treatment was safely administered in all cases. These exploratory findings support the rationale for future randomized controlled trials to further evaluate its impact on cognitive and affective functions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.